Adverum Biotechnologies Analyst Ratings
Adverum Biotechnologies Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 227.87% | Truist Securities | → $6 | Reiterates | Buy → Buy |
| 08/11/2023 | 118.58% | Chardan Capital | $2 → $4 | Upgrades | Neutral → Buy |
| 03/07/2023 | 9.29% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
| 11/11/2022 | 9.29% | Chardan Capital | $2.5 → $2 | Maintains | Neutral |
| 11/11/2022 | 63.93% | RBC Capital | $5 → $3 | Maintains | Sector Perform |
| 08/12/2022 | 36.61% | Chardan Capital | $3 → $2.5 | Maintains | Neutral |
| 07/07/2022 | 118.58% | Truist Securities | $3 → $4 | Upgrades | Hold → Buy |
| 07/23/2021 | 63.93% | Chardan Capital | $5 → $3 | Maintains | Neutral |
| 07/23/2021 | 63.93% | Cantor Fitzgerald | $23 → $3 | Downgrades | Overweight → Neutral |
| 07/23/2021 | 9.29% | SVB Leerink | $5 → $2 | Maintains | Market Perform |
| 05/03/2021 | 173.22% | SVB Leerink | → $5 | Downgrades | Outperform → Market Perform |
| 04/29/2021 | 227.87% | RBC Capital | → $6 | Downgrades | Outperform → Sector Perform |
| 04/29/2021 | 173.22% | Chardan Capital | $20 → $5 | Downgrades | Buy → Neutral |
| 04/29/2021 | 391.8% | Truist Securities | $30 → $9 | Downgrades | Buy → Hold |
| 04/29/2021 | 501.09% | SVB Leerink | $21 → $11 | Maintains | Outperform |
| 11/12/2020 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 08/11/2020 | 1047.54% | SVB Leerink | $20 → $21 | Maintains | Outperform |
| 05/13/2020 | 1211.48% | RBC Capital | → $24 | Initiates Coverage On | → Outperform |
| 05/05/2020 | 1047.54% | SunTrust Robinson Humphrey | → $21 | Upgrades | Hold → Buy |
| 05/05/2020 | 992.9% | SVB Leerink | $17 → $20 | Maintains | Outperform |
| 04/28/2020 | 828.96% | Goldman Sachs | → $17 | Initiates Coverage On | → Buy |
| 03/16/2020 | 828.96% | SVB Leerink | → $17 | Initiates Coverage On | → Outperform |
| 02/10/2020 | 992.9% | Chardan Capital | $10 → $20 | Upgrades | Neutral → Buy |
| 02/10/2020 | 1047.54% | Cantor Fitzgerald | $8 → $21 | Upgrades | Neutral → Overweight |
| 01/13/2020 | 992.9% | Piper Sandler | $14 → $20 | Reiterates | → Overweight |
| 09/13/2019 | 337.16% | SunTrust Robinson Humphrey | $12 → $8 | Maintains | Hold |
| 06/14/2019 | — | Raymond James | Reinstates | → Market Perform | |
| 11/05/2018 | 118.58% | Cantor Fitzgerald | $12 → $4 | Downgrades | Overweight → Neutral |
| 11/02/2018 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 11/02/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 09/21/2018 | 555.74% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/05/2023 | 227.87% | Truist證券 | →$6 | 重申 | 購買→購買 |
| 2023年08月11日 | 118.58% | 查爾丹資本 | $2→$4 | 升級 | 中性→購買 |
| 03/07/2023 | 9.29% | 拉登堡·塔爾曼 | →$2 | 開始承保 | →購買 |
| 2022年11月11日 | 9.29% | 查爾丹資本 | $2.5→$2 | 維護 | 中性 |
| 2022年11月11日 | 63.93% | 加拿大皇家銀行資本 | $5→$3 | 維護 | 行業表現 |
| 2022年08月12日 | 36.61% | 查爾丹資本 | $3→$2.5 | 維護 | 中性 |
| 07/07/2022 | 118.58% | Truist證券 | $3→$4 | 升級 | 持有→購買 |
| 07/23/2021 | 63.93% | 查爾丹資本 | $5→$3 | 維護 | 中性 |
| 07/23/2021 | 63.93% | 康託·菲茨傑拉德 | $23→$3 | 評級下調 | 超重→中性 |
| 07/23/2021 | 9.29% | SVB Leerink | $5→$2 | 維護 | 市場表現 |
| 05/03/2021 | 173.22% | SVB Leerink | →$5 | 評級下調 | 跑贏→市場表現 |
| 04/29/2021 | 227.87% | 加拿大皇家銀行資本 | →$6 | 評級下調 | 跑贏→板塊表現 |
| 04/29/2021 | 173.22% | 查爾丹資本 | $20→$5 | 評級下調 | 購買→中性 |
| 04/29/2021 | 391.8% | Truist證券 | $30→$9 | 評級下調 | 購買→Hold |
| 04/29/2021 | 501.09% | SVB Leerink | $21→$11 | 維護 | 跑贏大盤 |
| 2020年11月12日 | - | 雷蒙德·詹姆斯 | 升級 | 表現遜於→市場表現 | |
| 2020年08月11日 | 1047.54% | SVB Leerink | $20→$21 | 維護 | 跑贏大盤 |
| 2020/05/13 | 1211.48% | 加拿大皇家銀行資本 | →$24 | 開始承保 | →跑贏大盤 |
| 05/05/2020 | 1047.54% | SunTrust Robinson Humphrey | →$21 | 升級 | 持有→購買 |
| 05/05/2020 | 992.9% | SVB Leerink | $17→$20 | 維護 | 跑贏大盤 |
| 04/28/2020 | 828.96% | 高盛 | →$17 | 開始承保 | →購買 |
| 03/16/2020 | 828.96% | SVB Leerink | →$17 | 開始承保 | →跑贏大盤 |
| 02/10/2020 | 992.9% | 查爾丹資本 | $10→$20 | 升級 | 中性→購買 |
| 02/10/2020 | 1047.54% | 康託·菲茨傑拉德 | $8→$21 | 升級 | 中性→超重 |
| 2020/01/13 | 992.9% | 派珀·桑德勒 | $14→$20 | 重申 | →超重 |
| 2019年09月13日 | 337.16% | SunTrust Robinson Humphrey | $12→$8 | 維護 | 保持 |
| 2019年06月14日 | - | 雷蒙德·詹姆斯 | 恢復 | →市場表現 | |
| 2018年11月05日 | 118.58% | 康託·菲茨傑拉德 | $12→$4 | 評級下調 | 超重→中性 |
| 11/02/2018 | - | SunTrust Robinson Humphrey | 評級下調 | 購買→Hold | |
| 11/02/2018 | - | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 2018年09月21日 | 555.74% | 康託·菲茨傑拉德 | →$12 | 開始承保 | →超重 |
What is the target price for Adverum Biotechnologies (ADVM)?
Adverum BioTechnologies(ADVM)的目標價格是多少？
The latest price target for Adverum Biotechnologies (NASDAQ: ADVM) was reported by Truist Securities on September 5, 2023. The analyst firm set a price target for $6.00 expecting ADVM to rise to within 12 months (a possible 227.87% upside). 5 analyst firms have reported ratings in the last year.
Adverum BioTechnologies(納斯達克：advm)的最新目標價是由Truist證券於2023年9月5日報道的。這家分析公司將目標價定為6美元，預計ADM將在12個月內升至(可能上漲227.87%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?
Adverum BioTechnologies(ADVM)的最新分析師評級是什麼？
The latest analyst rating for Adverum Biotechnologies (NASDAQ: ADVM) was provided by Truist Securities, and Adverum Biotechnologies reiterated their buy rating.
分析師對Adverum BioTechnologies(納斯達克代碼：ADVM)的最新評級由Truist Securities提供，Adverum BioTechnologies重申了其買入評級。
When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?
Adverum BioTechnologies(ADVM)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Adverum BioTechnologies的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Adverum BioTechnologies的上一次評級是在2023年9月5日提交的，因此您應該預計下一次評級將在2024年9月5日左右的某個時候提供。
Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?
分析師對Adverum BioTechnologies(ADVM)的評級正確嗎？
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adverum Biotechnologies (ADVM) is trading at is $1.83, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Adverum BioTechnologies(ADVM)評級被重申，目標價在0.00美元至6.00美元之間。Adverum BioTechnologies(ADVM)目前的股價為1.83美元，在分析師的預測範圍內。